Avatar 1Avatar 2Avatar 3Avatar 4Avatar 5

Earn 10$ Cash for every Pro+ Friend you Refer!

Agios Pharm

Agios Pharm

AGIO · NASDAQ
AGIO · NASDAQ

Next Earnings: 13 Feb 2025

34.46
USD-0.89-2.52%

Latest News

    @bitcoinagile
    bitcoinagile

    AGIO D Long Setup for NASDAQ:AGIO by alihikmetharun #AGIO #btc #usdt #Crypto #coin #forex https://t.co/z7EV0Ux7Wi https://t.co/9PYdsrN5eG

    Analysts Recommendations

    Bullish

    Buy

    Strong Buy

    Buy

    Hold

    Sell

    Strong Sell

    Day Range

    34.11USD
    35.84USD

    52 Week Range

    21.18USD
    62.58USD

    Market Cap

    2.02BUSD

    lock-imagelock-image

    Get Full Access with Profit PRO

    See which Billionaires own this investment

    About

    General Information

    Type

    Common Stock

    Exchange

    NASDAQ

    Currency Code

    USD

    Currency Name

    US Dollar

    Country Name

    USA

    Country ISO

    US

    ISIN

    US00847X1046

    CUSIP

    00847X104

    Sector

    Healthcare

    Industry

    Biotechnology

    Fiscal Year End

    December

    IPO date

    -

    Updated At

    -

    Highlights

    PE Ratio

    2.96

    PEG Ratio

    -

    Book Value

    28.53

    Dividend Share

    -

    Dividend Yield

    -

    Earnings Share

    11.66

    Wall Street Target Price

    57

    EPS Estimate Current Year

    11.21

    EPS Estimate Next Year

    -5.796

    EPS Estimate Current Quarter

    1.11

    EPS Estimate Next Quarter

    -1.73

    Most Recent Quarter

    -

    Profitability

    Revenue TTM

    32,871,000

    Gross Profit TTM

    -266,584,992

    EBITDA

    -401,288,000

    Profit Margin

    2051.38%

    Return On Assets TTM

    -18.18%

    Return On Equity TTM

    53.66%

    Revenue Per Share TTM

    0.582

    Qtly Revenue Growth YOY

    21.20%

    Diluted Eps TTM

    11.66

    Qtly Earnings Growth YOY

    0.00%

    Valuation

    Trailing PE

    2.96

    Forward PE

    2

    Price Sales TTM

    59.7871

    Price Book MRQ

    1.2404

    Enterprise Value Revenue

    32

    Enterprise Value EBITDA

    -2

    Peers analysis

    • UCB SA ADR
      UCBJYUCB SA ADR

      99.44

      3.39%
    • Alnylam Pharmaceuticals Inc
      ALNYAlnylam Pharmaceuticals Inc

      279.00

      1.22%
    • CSL Ltd
      CSLLYCSL Ltd

      85.68

      0.87%
    • argenx SE
      ARGNFargenx SE

      625.30

      0.00%
    • UCB SA
      UCBJFUCB SA

      190.00

      0.00%
    • BioNTech SE
      BNTXBioNTech SE

      118.14

      -3.35%
    • Regeneron Pharmaceuticals Inc
      REGNRegeneron Pharmaceuticals Inc

      675.00

      -2.82%
    • CSL Limited
      CMXHFCSL Limited

      164.85

      -1.47%
    • argenx NV ADR
      ARGXargenx NV ADR

      648.94

      -0.54%
    • Vertex Pharmaceuticals Inc
      VRTXVertex Pharmaceuticals Inc

      439.62

      -0.08%